Sánchez-González José-María, De-Hita-Cantalejo Concepción, González-Rodríguez María Luisa, Fernández-Trueba-Fagúndez Ana, Ballesteros-Sánchez Antonio, Martinez-Perez Clara, Caro-Díaz Romina, Guzman Carla Montiel, González-Oyarce María Fernanda, Sánchez-González María Carmen
Department of Physics of Condensed Matter, Optics Area, Vision Sciences Research Group (CIVIUS), Pharmacy School, University of Seville, Seville, Spain.
Faculty of Pharmacy, Department of Pharmaceutical Technology, University of Seville, Seville, Spain.
Front Med (Lausanne). 2024 Jun 26;11:1264695. doi: 10.3389/fmed.2024.1264695. eCollection 2024.
Dry eye disease (DED) is a prevalent condition causing ocular discomfort and visual disturbances, often managed with artificial tears. This study aimed to assess and compare the efficacy of eye drops containing Crosslinked Hyaluronic Acid (CHA) with liposomes and crocin and standard Hyaluronic Acid (HA) for DED management.
A single-blind, longitudinal study was conducted on 24 participants (48 eyes), randomized to receive one of the two treatments. Ocular health measures, including the ocular surface disease index (OSDI) and the standard patient evaluation of eye dryness (SPEED) scores, were assessed at baseline and 6 weeks post-treatment using the Ocular Surface Analyzer.
CHA achieved a lipid layer thickness increase of 1.29 ± 1.08 Guillon pattern degree ( < 0.01), FNIBUT increase 0.64 ± 0.77 s (p < 0.01), MNIBUT increase1.28 ± 4.74 s ( = 0.19), OSDI decrease 11.72 ± 6.73 score points ( < 0.01) and SPEED decrease 1.16 ± 5.05 score points ( = 0.27). Significant reductions in the OSDI and SPEED scores post-treatment were observed with both treatments, indicating their effectiveness.
CHA with liposomes exhibits superior efficacy compared to standard HA eye drops in the management of DED. These findings highlight the potential for personalized treatment strategies incorporating CHA, indicating a more effective approach to DED management. However, further research is required to validate these results and investigate the long-term effects, which may pave the way for a data-driven and optimized approach to managing DED.
干眼症（DED）是一种常见病症，会导致眼部不适和视觉障碍，通常使用人工泪液进行治疗。本研究旨在评估和比较含交联透明质酸（CHA）与脂质体和藏红花素的滴眼液以及标准透明质酸（HA）治疗干眼症的疗效。
对24名参与者（48只眼）进行了一项单盲纵向研究，随机接受两种治疗中的一种。使用眼表分析仪在基线和治疗后6周评估眼部健康指标，包括眼表疾病指数（OSDI）和干眼标准患者评估（SPEED）评分。
CHA使脂质层厚度增加1.29±1.08 Guillon模式度（p<0.01），非侵入性泪膜破裂时间（FNIBUT）增加0.64±0.77秒（p<0.01），平均泪膜破裂时间（MNIBUT）增加1.28±4.74秒（p=0.19），OSDI降低11.72±6.73分（p<0.01），SPEED降低1.16±5.05分（p=0.27）。两种治疗后OSDI和SPEED评分均显著降低，表明它们的有效性。
与标准HA滴眼液相比，含脂质体的CHA在治疗干眼症方面表现出更高的疗效。这些发现突出了采用CHA的个性化治疗策略的潜力，表明这是一种更有效的干眼症管理方法。然而，需要进一步研究来验证这些结果并调查长期影响，这可能为数据驱动和优化的干眼症管理方法铺平道路。
